Navigation Links
Analysis Shows BYDUREON™ Was Not Associated with Clinically Relevant QT Prolongation in Patients with Type 2 Diabetes: Results Presented at ADA 2011
Date:6/24/2011

focus our efforts on making this once-weekly therapy available to patients and healthcare providers in the U.S."

BYDUREON received marketing authorization in the European Union earlier this month. In the U.S., the FDA issued a complete response letter for the BYDUREON New Drug Application in late 2010. The companies plan to submit a response, including results of the thorough QT (tQT) study, in the second half of 2011. The tQT study uses intravenous exenatide to achieve plasma exenatide concentrations expected with BYDUREON, including the concentrations expected in patients with renal impairment.

BYDUREON is the proposed brand name for exenatide extended-release for injectable suspension. It is an investigational medication for type 2 diabetes designed to deliver continuous therapeutic levels of exenatide in a single weekly dose. BYDUREON is a once-weekly formulation of exenatide, the active ingredient in BYETTA® (exenatide) injection, which has been available in the U.S. since June 2005 and is used in more than 70 countries worldwide to improve glycemic control in adults with type 2 diabetes.

Analysis Design

This analysis included 148 patients with type 2 diabetes from the BYDUREON arm of DURATION-1, a phase 3, randomized, open-label, comparator-controlled trial. Electrocardiogram (ECG) recordings were performed at baseline; once steady-state plasma exenatide concentrations had been achieved following at least 14 weeks of treatment; and in a subset of patients at 30 weeks of treatment or sooner if the patient left the study early. Board-certified cardiologists who were blinded to treatment assignment performed analyses (interpretations) of all ECG tracings.

About Diabetes

Diabetes affects nearly 26 million people in the U.S. and an estimated 285 million adults worldwide.(ii, iii) Approximately 90-95 percent of those affected have type 2 diabetes. Diabetes costs more than $174 billion per year in direc
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Alkermes, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Analysis Compares Cost-Effectiveness of Premixed Insulin Analogs to Long-Acting Insulin Analogs in the Long-Term Treatment of Type 2 Diabetes in the U.S.
2. Analysis Finds BYETTA® Associated with Lower Likelihood of Heart Failure Compared with Other Diabetes Therapies: Results Presented at ADA 2011
3. PRA Early Phase Leaders to Speak at Bioanalysis Forum
4. Dr. Assad Al-Ammar Joins Irvine Pharmaceutical Services as the New Minerals Analysis Manager in Response to the Growing Needs for USP Elemental Impurities Testing
5. Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries
6. Post Hoc Analysis from RECOVER Study Examined Effects of Neupro® (Rotigotine Transdermal System) on Surrogate Markers of Mood and Anhedonia in Parkinsons Disease
7. ForteBio Introduces New Biosensor for Kinetic Analysis and Screening of Mouse IgG Antibodies
8. Hip Resurfacing Implants - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
9. Reportlinker Adds Hip Replacement Implants - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
10. Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
11. Reportlinker Adds Hearing Aid Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... and Market Analysis to 2022 ... Dermatitis - India Drug Forecast and Market ...
(Date:1/15/2014)... novel wearable injector slightly larger than an Oreo cookie may ... prescription drugs in the large doses required to treat a ... and genetic disorders.  An emerging biologic drugs ... to analysts.   Many of these drugs will require a new ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
(Date:4/17/2014)... signs of chronic inflammation in non-cancerous prostate tissue may ... cancer than those with no inflammation, according to results ... Johns Hopkins Kimmel Cancer Center. , The link between ... with so-called high-grade prostate cancer those with a ... presence of the most aggressive and rapidly growing prostate ...
(Date:4/17/2014)... April issue of Experimental Biology and Medicine ... Rex Gaskins and Paul Kenis in the Institute ... the University of Illinois Urbana-Champaign describe their recent ... underlie a variety of cell functions including energy ... crucial roles in regulating normal cellular behavior, redox ...
(Date:4/17/2014)... A Northwestern University synthetic biology team has created ... create programmable therapeutics that could travel the body ... disease. , Engineering cell-based, biological devices that monitor ... in clinical synthetic biology. However, no existing technology ... a patient,s physiological state and respond in a ...
(Date:4/17/2014)... April 17, 2014-- Colic affects about one in five ... numerous pediatric visits during the first several months after ... symptoms was showing promise; however, the April 1, 2014 ... Sung, Valerie) reported on a study, "Probiotics and Infant ... L reuteri for infant colic did not ...
(Date:4/17/2014)... to ward off depression among retirees, particularly among those ... The Journals of Gerontology, Series B: Psychological ... " Internet Use and Depression Among Retired Older Adults ... authors report that Internet use reduced the probability of ... sample. , Late-life depression affects between 5 and ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Internet use may cut retirees' depression 2
... group based in Washington, D.C., has been working to,prevent ... on,the food chain is the primary way that we ... neurological and other health problems., In honor of ... tips for keeping your family mercury-free (and worry-free):, ...
... in fried foods, snacks, coffee upped chances of disease ... large amounts of acrylamide, a chemical commonly found in ... raise the risk of kidney cancer, especially in smokers, ... of a positive association between dietary acrylamide intake and ...
... Surface and Volume ... ... a global innovator of simulation software and technologies designed,to optimize product ... advanced mesh generation software. TGrid,technology is a specialized pre-processor for fluid ...
... May 9, 2008 More than 4,000 infection ... are expected to convene at a five-day conference ... issues facing their profession today. , Strategies for ... of healthcare-associated infections (HAIs) and emerging multidrug-resistant bacteria ...
... BIRMINGHAM, Ala., May 8 HealthSouth,Corporation (NYSE: HLS ... among other things, elect directors and provide an update ... May 2007., More than 88.5% of the outstanding ... in person or by proxy and the board,s,nominated slate ...
... Effort includes updated Web pages, brochure, advertisement, and,informational ... ROCKVILLE, Md., May 8 On May 8, ... launch a,nationwide outreach effort to raise awareness about ... near nuclear weapons testing facilities in,the mid-20th century. ...
Cached Medicine News:Health News:Amber Valletta on Preventing Mercury Exposure 2Health News:Amber Valletta on Preventing Mercury Exposure 3Health News:Acrylamide Raises Kidney Cancer Risk 2Health News:Acrylamide Raises Kidney Cancer Risk 3Health News:TGrid 5.0 Advances Automatic, High-Quality Meshing Tools for Increased Productivity 2Health News:TGrid 5.0 Advances Automatic, High-Quality Meshing Tools for Increased Productivity 3Health News:APIC conference to focus on patient safety and 'Targeting Zero' initiatives to reduce HAIs 2Health News:HealthSouth Board Re-Elected at Annual Shareholder Meeting 2Health News:HRSA Outreach Seeks to Raise Cancer Awareness Among People Who Lived Near Nuclear Sites or Mined Uranium 2Health News:HRSA Outreach Seeks to Raise Cancer Awareness Among People Who Lived Near Nuclear Sites or Mined Uranium 3
... unique DHEA-S-7kits feature a ... against the C-7 position ... with no cross-reactivity with ... RIA has been optimized ...
... based on the competition principle and the ... present in the sample and a fixed ... compete for the binding sites of a ... After one hour incubation the microtiterplate is ...
Inquire...
... It is a compact Latex based reagent kit ... well as to determine the level of RF ... patient sera. The kit includes antigen coated fine ... control sera in plastic squeezable dropping bottles, re-usable ...
Medicine Products: